EWS-FLI1-mediated tenascin-C expression promotes tumour progression by targeting MALAT1 through integrin α5β1-mediated YAP activation in Ewing sarcoma
Menée à l'aide de lignées cellulaires, de tissus de sarcome d'Ewing et d'un modèle murin, cette étude met en évidence un mécanisme par lequel l'expression de la ténascine C, induite par l'oncoprotéine EWS-FLI1, favorise la progression tumorale en agissant sur l'ARN non codant MALAT1 via l'activation de la protéine YAP par l'intégrine alpha1bêta5
Background : The extracellular matrix has been critically associated with the tumorigenesis and progression of Ewing sarcoma (ES). However, the regulatory and prognostic roles of tenascin-C (TNC) in ES remain unclear. Methods : TNC expression was examined in specimens by immunohistochemistry, and the association of TNC expression with ES patient survival was also analysed. TNC-knockout cell lines were constructed using CRISPR/Cas9 methods. In vitro experiments and in vivo bioluminescent imaging using BALB/c nude mice were conducted to evaluate the effect of TNC on ES tumour progression. RNA sequencing was performed, and the underlying mechanism of TNC was further explored. Results : TNC was overexpressed in ES tissue and cell lines, and TNC overexpression was associated with poor survival in ES patients. TNC enhanced cell proliferation, migration and angiogenesis in vitro and promoted ES metastasis in vivo. The oncoprotein EWS-FLI1 profoundly increased TNC expression by directly binding to the TNC promoter region. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) upregulation induced by Yes-associated protein (YAP) activation was responsible for TNC-regulated ES tumour progression. Activated integrin
α5β1 signalling might be correlated with YAP dephosphorylation and nuclear translocation. Conclusions
:
TNC may promote ES tumour progression by targeting MALAT1 through integrin α5β1-mediated YAP activation.